Anticoagulants Market Report

Heart arrhythmias most commonly occur in people with atrial fibrillation which is disease is expected to affect 6-12 million people in the United States by 2050 and 17.9 million people in Europe by 2060. Atrial fibrillation is a significant risk factor for ischemic stroke, resulting in a significant economic burden as well as morbidity and death. In accordance with the CDS, around 454,000 hospitalisations with Atrial Fibrillation even as primary diagnosis happen in the United States each year. Each year, this condition causes around 158,000 fatalities. The biggest burden is observed in countries with a high socio-demographic index; however, the most recent rise has been seen in countries with a moderate socio-demographic index. According to the National Library of Medicine, the absolute burden of atrial fibrillation may increase by more than 60% by 2050. As a result, all of these factors contribute to market expansion during the forecast period.

Rising awareness of health and strict regulatory standards are being identified as major threats in the long run for the anticoagulant market. With a growing awareness of health and well-being, consumers are looking for safer and more efficient treatment choices, leading manufacturers to constantly come up with new innovations. Moreover, as regulatory frameworks evolve, there are more rigorous compliance demands which make it more complex and costly to introduce new anticoagulant products to the market. Stringent regulations and an increased risk of treatment-related side effects are expected to restrict market size during the forecast period. Growing public awareness of adverse effects such as hemoptysis, malena, menorrhagia, epistaxis, hematuria and bleeding gums has hampered the expansion of the anticoagulant drugs market. With developments in technology and anticoagulant quality, the rising cost of the drugs is creating a challenge to the market's growth.

Companies are at the forefront of driving market expansion through innovation and development. By investing in new technologies, processes, and products, companies improve their competitive advantage and meet changing consumer demands. For instance, in June 2024, InsightRX and Northern Arizona Healthcare (NAH) revealed their plan to offer InsightRX's precise dosing software for heparin treatment to NAH's pharmacists at Flagstaff Medical Center. NAH anticipates that this implementation will reduce the time required to therapeutically administer unfractionated heparin to hospitalized patients for treating and preventing blood clots, ultimately enhancing patient results. Additionally, in June 2022, Teva UK has launched a generic version of apixaban, one of the oral anticoagulants that directly inhibits the factor X-factor XA, inhibiting thrombin production and blood clot development.

North America is expected to have a significant market share in the global anticoagulants market. Since there is a high demand for novel products and the increasing frequency of cardiovascular disorders in this region. Also, the Centers for Disease Control and Prevention reported in February 2022 that around 659,000 people every year die of heart disease. As the prevalence of cardiovascular disease rises, there is an increasing demand for anticoagulants in the region, bolstering the market. Additionally, the presence of top pharma and biotech businesses active in therapeutic development, as well as the availability of well-established healthcare infrastructure, is supporting the overall regional market's expansion to a considerable extent. Thus, all of the aforementioned factors, such as rising chronic diseases and product launches by leading market players, contribute to the growth of the anticoagulant market in North America.